File Download
There are no files associated with this item.
Links for fulltext
(May Require Subscription)
- Publisher Website: 10.1016/j.ijpharm.2013.03.050
- Scopus: eid_2-s2.0-84884125790
- Find via
Supplementary
-
Citations:
- Scopus: 0
- Appears in Collections:
Article: Active drug targeting: Lessons learned and new things to consider
Title | Active drug targeting: Lessons learned and new things to consider |
---|---|
Authors | |
Issue Date | 2013 |
Citation | International Journal of Pharmaceutics, 2013, v. 454, n. 1, p. 525-526 How to Cite? |
Abstract | There is "hype" surrounding passive and active drug targeting of diseased tissues in vivo. The most common example of passive targeting is the utilisation of the "enhanced permeation and retention" phenomenon to target solid tumours and inflamed tissues. Alternatively, targeting moieties or "ligands" could be conjugated to the delivery system offering "actively" targeted delivery systems. The targets are usually receptors that are up-regulated in the biological areas of interest. Targeted drug delivery has been proposed to treat many diseases, such as cardiovascular diseases and diabetes. However, the most important application of targeted drug delivery is to treat cancerous tumours. Standardisation of in vitro and in vivo assays currently in place to assess the targeting efficiency of such systems is of utmost importance since heterogeneity in targeting assays and target validation could easily bias conclusions made affecting the future perspective of the field of active drug targeting. © 2013 Published by Elsevier B.V. |
Persistent Identifier | http://hdl.handle.net/10722/349009 |
ISSN | 2023 Impact Factor: 5.3 2023 SCImago Journal Rankings: 0.954 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Al-Jamal, Khuloud T. | - |
dc.date.accessioned | 2024-10-17T06:55:37Z | - |
dc.date.available | 2024-10-17T06:55:37Z | - |
dc.date.issued | 2013 | - |
dc.identifier.citation | International Journal of Pharmaceutics, 2013, v. 454, n. 1, p. 525-526 | - |
dc.identifier.issn | 0378-5173 | - |
dc.identifier.uri | http://hdl.handle.net/10722/349009 | - |
dc.description.abstract | There is "hype" surrounding passive and active drug targeting of diseased tissues in vivo. The most common example of passive targeting is the utilisation of the "enhanced permeation and retention" phenomenon to target solid tumours and inflamed tissues. Alternatively, targeting moieties or "ligands" could be conjugated to the delivery system offering "actively" targeted delivery systems. The targets are usually receptors that are up-regulated in the biological areas of interest. Targeted drug delivery has been proposed to treat many diseases, such as cardiovascular diseases and diabetes. However, the most important application of targeted drug delivery is to treat cancerous tumours. Standardisation of in vitro and in vivo assays currently in place to assess the targeting efficiency of such systems is of utmost importance since heterogeneity in targeting assays and target validation could easily bias conclusions made affecting the future perspective of the field of active drug targeting. © 2013 Published by Elsevier B.V. | - |
dc.language | eng | - |
dc.relation.ispartof | International Journal of Pharmaceutics | - |
dc.title | Active drug targeting: Lessons learned and new things to consider | - |
dc.type | Article | - |
dc.description.nature | link_to_subscribed_fulltext | - |
dc.identifier.doi | 10.1016/j.ijpharm.2013.03.050 | - |
dc.identifier.scopus | eid_2-s2.0-84884125790 | - |
dc.identifier.volume | 454 | - |
dc.identifier.issue | 1 | - |
dc.identifier.spage | 525 | - |
dc.identifier.epage | 526 | - |
dc.identifier.eissn | 1873-3476 | - |